It's ESMO season, and 10 of 12 Presidential abstracts report 'meeting primary endpoints.' Seven have declared a survival win, including the VOLGA trial now under priority review.
With 2L daraxonrasib doubling mOS vs chemo for mPDAC in RASolute 302 (now under FDA review), focus is already shifting towards 1L (RASolute 303) and even adjuvant use (RASolute 304).